To estimate the glycemic control among Asthma and Chronic Obstructive Disease (COPD) Patients prescribed with cor- ticosteroids and to identify their adverse effects. A prospective cross-sectional study was conducted in pulmonology department at multi-speciality hospital after obtaining ethical approval. Total- ly, 74 patients were enrolled based on inclusion criteria. Glycemic levels were monitored using random blood sugar (RBS) levels before and after steroid administration. Out of 74 patients, 28 patients received budesonide alone, 27 patients received budesonide and oral methyl prednisolone combination and 13 patients received fluticasone propionate as inhalation therapy. RBS values were monitored before and after administration of steroid, which showed hyperglycemia in three diabetic patients (17.65%) with asthma and COPD. There were no significant changes (p value >0.05) in RBS levels before and after steroid intake among non- diabetic and diabetic patients in both asthma and COPD. Steroid stewardship program conducted showed that glycemic monitoring is essential in diabetic patients with asthma and COPD to prevent hyperglycemic episodes. Thereby, we conclude that accurate insu- lin dosage can be administered with periodic RBS level monitoring, which can be implemented by a steroid stewardship program.

Articles Details

NAMES:

ONLINE ISSN:2456-8244

Keywords: Corticosteroids, Asthma, COPD, Glycemic control, Stewardship

DOI:

Abstract FullText PDF

REFERENCES

1. Liu D, Ahmet A, Ward L, Krishnamoorthy P, Mandelcron ED, Leigh R, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma ClinImmunol. 2013;9(1):30
2. Price D, Bourdin A. Proactive Risk Management: A Novel Approach to Embedding Oral Corticosteroid Stewardship into Asthma Care. Eur.Med.J. 2022;10[Suppl 2]:2-10
3. Kalra S, Kumar A, Sahay R. Steroid stewardship. Indian J Endocro Metab 2022; 26(1):13-16
4. Pagano G, Cavallo-Perin P, Cassader M, et al. An in vivo and in vitro study of the mechanism of prednisone-induced insulin resistance in healthy subjects.J Clin Invest. 1983; 72(5):1814-1820.
5. Ruzzin J, Wagman AS, Jensen J. Glucocorticoid-induced insulin resistance in skeletal muscles: defects in insulin signalling and the effects of a selective glycogen synthase kinase-3 inhibitor.Diabetologia. 2005; 48(10):2119-2130.
6. Clore JN, Thurby-Hay L. Glucocorticoid-induced hyperglycemia. EndocrPract. 2009; 15(5):469-474
7. Agiostratidou G, Anhalt H, Ball D, Blonde L, Gourgari E, Harriman KN. Standardizing Clinically Meaningful Outcome Measures Beyond HbA1c for Type 1 Diabetes: A consensus Report of the American Association of Clinical Endocrinologists, the American Association of Diabetes Educators, the American Diabetes Association, the Endocrine Society, JDRF International, The Leona M. and Harry B. Helmsley Charitable Trust, the Pediatric Endocrine Society, and the T1D Exchange. Diabetes care.2017;40(12):1622-1630
8. Tamez-Pérez HE, Quintanilla-Flores DL, Rodríguez-Gutiérrez R, and González-González JG, Tamez-Peña AL. Steroid hyperglycemia: Prevalence, early detection and therapeutic recommendations: A narrative review. World J Diabetes. 2015;6(8):1073–1081.
9. Suissa S, Barnes PJ. Inhaled corticosteroids in COPD the case against. EurRespir J. 2009;34(1):13–16.
10. De Coster DA, Jones M. Tailoring of corticosteroids in COPD management. CurrRespir Care Rep. 2014;3(3):121–132
11. Blakey J, Chung LP, McDonald VM, Ruane L, Gornall J, Barton C, et al. Oral corticosteroids stewardship for asthma in adults and adolescents: A position paper from the thoracic society of Australia and New Zealand. Respirology 2021; 26(12):1112-1130
12. Cole JL. Effects of steroid stewardship on glycemic control in acute exacerbations of chronic obstructive pulmonary disease patients. ClinRespir J. 2023:17(5)478-484.
13. Rana MA, H. Siddiqui M, Raza S, Tehreem K, MahmoodMFUllah, Javed M, et al. Incidence of Steroid-induced Diabetes in COVID-19 patients. PJ M H S. 2021;15(10):2595–2596
14. Aryal A, Kunwar K, Shadvar S, Kharel S, Ramasamy R, Shashidhar G, et al. Study on Steroid Utilization Pattern in a Tertiary Care Teaching Hospital. Indian J. Pharm.Prac. 2017;10(2):96–103
15. D’cruz R, Reddy N, Marise DL, H.J. DG. PRS81 - Prescribing pattern and use of steroids among asthmatic patients in a tertiary care hospital. Value in Health. 2018; 21:S417.
16. Haikarainen J, Rytilä P, Roos S, Metsärinne S, Happonen A. Dose uniformity of budesonide Easyhaler® under simulated real-life conditions and with low inspiration flow rates. Chronic Respiratory Disease. 2017;15(3):265–271
17. J. C. M. Hoekx, Hedlin G, Pedersen W, RitvaSorva, Hollingworth K, Efthimiou J. Fluticasone propionate compared with budesonide: a double-blind trial in asthmatic children using powder devices at a dosage of 400 μg·day-1.Eur. Respir.J 1996;9(11):2263–2272.
18. National Asthma Council Australia. Australian Asthma Handbook, version 1.3. Melbourne: National Asthma Council Australia, 2017. [Accessed 05 Apr 2024.]Available from https://www.asthmahandbook.org.au/
19. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. 2018.[Accessed 05 Apr 2024.]Available from https://ginasthma.org/gina-reports/
20. Suehs CM, Menzies-Gow A, Price D, Bleecker ER, Canonica GW, Gurnell M, et al. Expert Consensus on the Tapering of Oral Corticosteroids for the Treatment of Asthma: A Delphi Study. Am J RespirCrit Care Med.2021;203(7):871-881
21. Price DB, Trudo F, Voorham J, Xu X, Kerkhof M, Ling ZhiJie J, et al. Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study. J Asthma  Allergy. 2018 ;11:193–204
22. Sweeney J, Patterson CC, Menzies?Gow A, Niven RM, Mansur AH, BucknallC,et.al. Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross?sectional data from the Optimum Patient Care Research Database and the British Thoracic Difficult Asthma Registry. Thorax 2016; 71(4): 339–346